DVA · Q2 2025 Earnings
CautiousDaVita
Reported August 5, 2025
30-second summary
Revenue grew 6.0% YoY to $3.38B with adjusted EPS of $2.95, but the headline obscures a messier story underneath: the February cyber incident drove a sustained spike in patient mistreatment rates that has now forced management to assume mistreatments stay flat vs. 2024 in H2 (vs. prior expectation of decline), pulling FY treatment growth guidance to -75 to -100bps and RPT ex-binders to ~2.25% from ~3%. Management held the FY adjusted operating income and EPS ranges intact only through cost-per-treatment outperformance and a $40M IKC timing pull-forward from 2024 plan year — neither a recurring tailwind.
Headline numbers
EPS
Q2 FY2025
$2.95
Revenue
Q2 FY2025
$3.38B
+6.0% YoY
Free cash flow
Q2 FY2025
$0.16B
Operating margin
Q2 FY2025
15.9%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $3.38B | +6.0% |
| EPS | $2.95 | — |
| Operating margin | 15.9% | — |
| Free cash flow | $0.16B | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| U.S. Dialysis | $2.913B | +3.2% |
| Integrated Kidney Care (IKC) | $0.152B | +44.8% |
| International Dialysis | $0.325B | +7.6% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| U.S. Dialysis Treatments per Day | 92,131 |
| Normalized Non-Acquired Treatment Growth YoY | -0.8% |
| Revenue per Treatment | $404.58 |
| Patient Care Costs per Treatment | $268.36 |
| Total Dialysis Centers | 3,175 |
| Total Dialysis Patients | 283,100 |
| Risk-Based IKC Patients | 64,400 |
| Annualized Risk-Based Medical Spend | $5.3 billion |
Management tone
Javier opened the call with an unusually forward-looking clinical framing — explicitly invoking a "new wave of clinical innovation" combining HDF/middle-molecule dialyzers, GLP-1 and SGLT-2 adoption, AI-enabled care personalization, and IT-driven hospitalization prediction protocols. The framing positions DaVita's volume problem as solvable but multi-year, and pairs it with a reaffirmation of the FY adjusted OI range of $2.01B–$2.16B and adjusted EPS range of $10.20–$11.30 "despite the negative impact of the cyber incident." The tone is confident on cost discipline and long-term clinical levers, defensive on near-term volume.
Across five analyst exchanges in Q&A, the posture was defensive but specific. The recurring construction was "the cyber impact is behind us on admits, but mistreatments persisted longer than we expected and we're not assuming they decline in H2." That precise hedge — issued repeatedly when pressed by Barclays, Wolfe and Deutsche Bank — signals management is no longer willing to bake recovery into the model and prefers to be judged against a flat-mistreatment baseline.
On mortality, Joel explicitly rejected the "structural" framing from Deutsche Bank's Peter Chickering ("I wouldn't say it's a structural issue, but just our anticipation for the next couple of quarters, we brought it down a bit"), and Javier reframed elevated mortality as a national, COVID-holdover issue requiring multi-year mitigation through HDF/middle-molecule dialyzers, GLP-1 adoption (currently low-teens % penetration in the dialysis population), and IT protocols. Javier's phrasing to Bank of America — "you should think about it in years and not just a couple quarters" — is the clearest tone signal in the call: do not expect a 2025 or 2026 inflection in volumes from these initiatives.
The IKC disclosure was unusually candid. When pressed by UBS's AJ Rice on whether the $40M Q2 benefit reflected better underlying trends, management volunteered it was pure timing with zero net full-year impact — a deliberate choice to dampen any narrative that IKC is inflecting.
Q&A highlights
Andrew Mock · Barclays
How are census and treatments tracking post-cyber attack, and how should we interpret the elevated mistreatment rates persisting into the back half if the cyber impact is largely behind?
Management explained that the cyber incident caused a spike in mistreatment rates (0.1% delta) in April-May that didn't follow the typical seasonal decline pattern. While admit challenges normalized within weeks as expected, the mistreatment spike was unexpected and led to revised full-year guidance assuming mistreatment rates flat year-over-year in H2 (vs. prior expectation of decline). Javier added context that mortality and mistreatment are the real issues to address through better molecule clearance, increased GLP-1 adoption, and improved IT protocols.
Peter Chickering · Deutsche Bank
How are you maintaining OI guidance despite worse treatment growth and RPT at lower end? What is driving the offset, and why would mistreatments become a structural headwind if patients need treatments to survive?
Management attributed the OI bridge primarily to cost per treatment improvements (labor productivity in U.S. dialysis) and a ~$10M international one-time benefit in Q2. On mistreatments, Javier clarified it's not structural—the company is assuming mistreatment rates roughly flat vs. 2024 for H2 based on flu and cyber impacts in H1. He emphasized the real focus should be on mortality reduction through better molecule clearance, GLP-1 adoption, and IT protocols, noting the company is not seeing upstream GLP-1 impact in admits yet despite industry discussion.
AJ Rice · UBS
Was the $40M IKC revenue pull-forward truly a timing issue or a sign of better underlying business trends? Also, why did the cyber incident impact revenue per treatment?
Management confirmed the $40M IKC benefit in Q2 was entirely 2024 plan year revenue recognized early due to gaining actuarial/accounting confidence in shared savings earlier than expected (Q2 vs. expected Q3-Q4). No net positive for full-year OI. On RPT impact from cyber: prior authorizations and data gathering on claims either went manual or were delayed, reducing claim approvals in Q2. Additionally, older denied claims being re-worked faced timing challenges and higher bad debt, though this impact is expected to end in H2.
Justin Lake · Wolf Research
What is the updated revenue per treatment ex-binders assumption, and what was the cyber impact to RPT in Q2? Also, on mistreatments, what was the year-over-year growth rate in H1, and how does the non-acquired volume decline compare to total volume?
Management revised RPT ex-binders from ~3% to ~2.25% for full year, driven by the cyber incident impact. Cyber impact to RPT in Q2 was 40-50 basis points. Mistreatment rates increased ~50 bps year-over-year in H1 (worse in Q1 than Q2). Non-acquired treatment growth is expected to be ~down 50 bps for the year (vs. total down 75-100 bps), with Q3 worse and Q4 better sequentially. Management resisted deep NAG modeling, noting prior-year census shape dynamics matter.
Kevin Fishbeck · Bank of America
Why is mortality persistently elevated versus pre-COVID levels, and what is the timing for the three-pronged mitigation plan (better molecule clearance, GLP-1s, IT protocols) to impact results?
Management attributed elevated all-cause mortality nationally (not just DaVita kidney) to COVID holdovers: delayed care and sicker comorbid populations dying faster. This is a national issue, not kidney-specific. On mitigation timing: all three initiatives (HDF/dialyzers, GLP-1 adoption, hospitalization prediction protocols) will be gradual and incremental, playing out over years not quarters. The company emphasized it is not passively waiting but actively implementing—noting this mirrors the 20-year pre-COVID era of dialysis-driven mortality improvements.
What to watch into next quarter
Mistreatment rate trajectory in Q3 — H2 guide assumes flat YoY vs. 2024; any further deterioration would force a second volume guide cut and likely pressure the FY EPS range. Watch whether the H1 ~50bps YoY increase narrows.
RPT ex-binders progression — full-year guide is now ~2.25%; with Q2 RPT at $404.58 and cyber impact contained to Q2, Q3 RPT should show a step-up. A sub-$408 print would imply further pressure on the FY guide.
IKC underlying trend ex-pull-forward — Q3 IKC revenue will normalize without the $40M 2024 timing benefit. Watch whether the run-rate supports the unchanged FY ~-$20M OI guide or signals slippage.
Cost-per-treatment durability — $268.36 in Q2 with labor productivity cited as the swing factor. If wage inflation reaccelerates or training costs rise on volume actions, the offset funding OI guidance erodes.
GLP-1 admit impact — management said no upstream impact "yet" despite industry discussion. First signs of reduced ESRD admits from GLP-1 adoption would be a multi-year structural headwind to census; watch the next NAG print.
Sources
- DaVita Inc. Q2 2025 Earnings Press Release (SEC Form 8-K Exhibit 99.1), filed 2025-08-05.
- DaVita Inc. Q2 2025 Earnings Call transcript (prepared remarks and Q&A).
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.